Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists show how molecular switch helps pancreatic cancer beat drugs

29.01.2010
Researchers at the Moores Cancer Center at the University of California, San Diego, have found one reason that pancreatic cancer tumors are so difficult to treat with drugs. They have shown how a molecular switch steps up pancreatic cancer cell survival as well as resistance to a standard chemotherapy drug, and have identified alternate routes cancer cells take to avoid the effects of the therapy.

The findings, by a group led by Andrew M. Lowy, MD, professor of surgery and chief of surgical oncology at the UCSD School of Medicine and the Moores UCSD Cancer Center, are reported online and will appear February 1 in the journal Cancer Research. The study provides new insights into pancreatic cancer development and new potential drug targets and treatment strategies against the disease.

"To understand how to treat pancreatic cancer tumors, we need to better understand their circuitry and behavior," Lowy said.

Pancreatic cancer is a particularly deadly cancer, fast-moving and difficult to detect early. It's estimated that more than 35,000 people died from pancreatic cancer last year in the United States.

RON is a signaling protein known as a tyrosine kinase, essentially a switch that turns on various activities in cells. Previous work in Lowy's lab showed that RON is overexpressed in a majority of precancerous and pancreatic cancer cells, and could also help cells resist dying. The researchers wanted to find out what role, if any, RON played in pancreatic cancer development and progression.

In a series of experiments, the researchers showed that RON sends signals that regulate the activity of genes that help tumors cells survive, "implying RON is a potent survival signal for pancreatic cancer cells," Lowy said.

To see the effects of reducing or blocking RON activity, the team shut down RON expression in pancreatic cancer cells using a molecular technique called "gene silencing," and then used those cells to establish tumors in mice. Those tumors were treated with gemcitabine, the most common chemotherapy drug used to treat pancreatic cancer patients. Tumors in which RON was silenced were much more sensitive to the chemotherapy than the RON-expressing cancer cells.

"This is the first demonstration that RON-directed therapy in an animal model can sensitize tumors to chemotherapy," Lowy said. Yet, the scientists found that the cancer cells and tumors were eventually able to bypass the silencing agent as well as the drug's effects, and continued to grow.

About 50 percent of the tumor cells re-expressed RON. The researchers also found that the tumor cells activated other growth proteins, including epidermal growth factor receptor (EGFR), to enable them to continue to grow.

"This is what most tumors do," Lowy said, explaining that clinically, pancreatic cancer tumors often respond to therapy at first, only to begin growing again. "We know that diseases such as pancreatic cancer are too complex for one drug to be effective. If we can learn to predict the results of RON-directed therapy, maybe we can combine it with an EGFR-directed therapy, for example, to take away tumor escape routes."

Lowy explained that scientists still need far more information about RON's part in pancreatic cancer development and progression. "We need to figure out which tumors are relying on RON," he said. "If we could develop biomarkers to identify which tumors are going to be susceptible to RON-targeted therapy, then we can begin to figure out what tumors do to escape such treatments."

Other contributors include Jocelyn Logan-Collins, Ryan M. Thomas, Rebecca McClaine, University of Cincinnati; Susan E. Waltz, William Stuart, University of Cincinnati College of Medicine; Bruce Aronow, Cincinnati Children's Hospital; Peter Yu, Dawn Jaquish, Evangeline Mose, Randall French, UCSD School of Medicine; and Robert Hoffman, UCSD School of Medicine and AntiCancer, Inc., San Diego.

Funding support came from several grants from the National Institutes of Health.

The Moores UCSD Cancer Center is one of the nation's 40 National Cancer Institute-designated Comprehensive Cancer Centers, combining research, clinical care and community outreach to advance the prevention, treatment and cure of cancer. For more information, visit http://health.ucsd.edu/cancer. The Ludwig Institute for Cancer Research (www.licr.org) is an international organization with branches in 10 countries.

Steve Benowitz | EurekAlert!
Further information:
http://www.ucsd.edu

More articles from Life Sciences:

nachricht Topologische Quantenchemie
21.07.2017 | Max-Planck-Institut für Chemische Physik fester Stoffe

nachricht Topological Quantum Chemistry
21.07.2017 | Max-Planck-Institut für Chemische Physik fester Stoffe

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: 3-D scanning with water

3-D shape acquisition using water displacement as the shape sensor for the reconstruction of complex objects

A global team of computer scientists and engineers have developed an innovative technique that more completely reconstructs challenging 3D objects. An ancient...

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

Ultrathin device harvests electricity from human motion

24.07.2017 | Power and Electrical Engineering

Scientists announce the quest for high-index materials

24.07.2017 | Materials Sciences

ADIR Project: Lasers Recover Valuable Materials

24.07.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>